Publication | Closed Access
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
67
Citations
10
References
2017
Year
Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaPlcg2 Resistance MutationsHematologyImmunologyPathologyIbrutinib TreatmentAdult T-cell Leukemia-lymphomaImmunotherapyMedicineCell Biology
| Year | Citations | |
|---|---|---|
Page 1
Page 1